Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ • Healthcare

$47.24

-$0.03 (-0.1%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$47.84

Day Range$47 - $47.86

Avg. Volume (3M)279K

Market Cap$874M

P/E Ratio2.7

52 Week Range

$24.95$52.24

Next EarningsIn 51 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$78.7M100%

Gross Profitminus cost of goods$70.1M89%

Operating Incomeminus R&D and overhead$23.5M30%

Net Incomeminus taxes and the rest$17.2M22%

In plain terms: out of every $100 in revenue, Rigel Pharmaceuticals, Inc. keeps $22 as net profit.

Fundamentals & Financials

Revenue (TTM)

$276.7M

Net Income (TTM)

$321.9M

EPS (TTM)

$17.67

ROA (TTM)

61.78%

Current Ratio

1.95

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+66.5%Q3 2025$3.28

+57.0%Q4 2025$1.46

-14.3%Q1 2026$1.14

-40.5%Q2 2026$0.44

+903.9%Q3 2026$0.88

Nov 3

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on commercial and clinical therapies for blood disorders, cancer, and immune-mediated disease. In FY2025, it recorded $294.3 million in revenue. Its marketed portfolio centers on medicines for defined hematology and oncology settings in the United States.

Name

Rigel Pharmaceuticals, Inc.

CEO

Raul R. Rodriguez

Website

www.rigel.com

Industry

Healthcare

Year Founded

1996

Employees

173

Today's Snapshot

AI-generated

RIGL closed slightly lower at 47.24, in line with a flat sector.

Trading Volume

Below 10d avg (191.7K)

187.1K

vs S&P 500 Today

Underperforming Market

-1.01%

Updated: September 11, 2026 at 20:17 UTC

Technical Indicators

4 Buy3 Neutral1 Sell

RIGL shows a constructive technical profile driven by a strong trend reading and supportive momentum while volume signals are mixed. The ADX is robust around 36.8, indicating a decisive trend, and momentum measures together with a positive MACD component favor near-term strength despite neutral RSI. Price sits above most medium and long-term moving averages even though the shortest averages are slightly higher than the current quote, reflecting recent consolidation. Volatility is moderate with an ATR near 1.67, but on-balance volume remains negative, suggesting limited buying participation. Technical takeaway: Buy.

All signals